Gvoke Kit is a drug owned by Xeris Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 22, 2036. Details of Gvoke Kit's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11590205 | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents |
Apr, 2036
(11 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Gvoke Kit's patents.
Latest Legal Activities on Gvoke Kit's Patents
Given below is the list of recent legal activities going on the following patents of Gvoke Kit.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Issue Date Used in PTA Calculation Critical | 28 Feb, 2023 | US11590205 |
| Email Notification Critical | 28 Feb, 2023 | US11590205 |
| Recordation of Patent Grant Mailed Critical | 28 Feb, 2023 | US11590205 |
| Issue Notification Mailed Critical | 08 Feb, 2023 | US11590205 |
| Application Is Considered Ready for Issue Critical | 24 Jan, 2023 | US11590205 |
| Dispatch to FDC | 24 Jan, 2023 | US11590205 |
| Mail Response to 312 Amendment (PTO-271) Critical | 23 Jan, 2023 | US11590205 |
| Email Notification Critical | 23 Jan, 2023 | US11590205 |
| Response to Amendment under Rule 312 Critical | 13 Jan, 2023 | US11590205 |
| Pubs Case Remand to TC Critical | 12 Jan, 2023 | US11590205 |
US patents provide insights into the exclusivity only within the United States, but Gvoke Kit is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Gvoke Kit's family patents as well as insights into ongoing legal events on those patents.
Gvoke Kit's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Gvoke Kit's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 22, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Gvoke Kit Generic API suppliers:
Glucagon is the generic name for the brand Gvoke Kit. 2 different companies have already filed for the generic of Gvoke Kit, with Amphastar Pharms Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Gvoke Kit's generic
Alternative Brands for Gvoke Kit
Gvoke Kit which is used for quickly raising blood sugar levels in cases of severe hypoglycemia., has several other brand drugs in the same treatment category and using the same active ingredient (Glucagon). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||
|---|---|---|---|---|---|---|
| Xeris |
| |||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Glucagon. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Amphastar Pharms Inc |
| ||
| Zealand Pharma |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Glucagon, Gvoke Kit's active ingredient. Check the complete list of approved generic manufacturers for Gvoke Kit
About Gvoke Kit
Gvoke Kit is a drug owned by Xeris Pharmaceuticals Inc. It is used for quickly raising blood sugar levels in cases of severe hypoglycemia. Gvoke Kit uses Glucagon as an active ingredient. Gvoke Kit was launched by Xeris in 2019.
Approval Date:
Gvoke Kit was approved by FDA for market use on 10 September, 2019.
Active Ingredient:
Gvoke Kit uses Glucagon as the active ingredient. Check out other Drugs and Companies using Glucagon ingredient
Treatment:
Gvoke Kit is used for quickly raising blood sugar levels in cases of severe hypoglycemia.
Dosage:
Gvoke Kit is available in solution form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1MG/0.2ML (1MG/0.2ML) | SOLUTION | Prescription | SUBCUTANEOUS |